ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Hold" by Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $5.00. The company recently reported a quarterly loss of $0.11 per share, beating analyst estimates, and revenue of $19.25 million, which slightly exceeded expectations. Institutional investors hold approximately 41.1% of the stock.
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded ADC Therapeutics (NYSE:ADCT) from a "sell" to a "hold" rating. The company reported a quarterly loss of $0.11 per share, beating analyst estimates, with revenue of $19.25 million also exceeding expectations. Despite mixed analyst coverage, the stock has a consensus "hold" rating and an average target price of $6.25, with institutional investors owning approximately 41.1% of the shares.
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing
Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, have disclosed a 9.69% ownership stake in ADC Therapeutics SA (ADCT) via a 13G filing. As of June 30, 2026, they beneficially own 12,326,184 common shares, held through funds and separately managed accounts, with shared voting and dispositive power. This passive investment indicates the shares were acquired in the ordinary course of business, not for influencing control.
ADC Therapeutics Q2 Earnings Call Highlights
ADC Therapeutics reported Q2 2026 net product revenue for ZYNLONTA of $18.6 million, a slight increase from the prior year. The company is re-evaluating its regulatory strategy for the LOTIS-5 study after the FDA raised "substantial concerns" regarding the benefit-risk profile and treatment verification. Meanwhile, enrollment for the LOTIS-7 study is complete, and the company plans to seek breakthrough therapy designation for the ZYNLONTA-glofitamab combination, while also reducing operating expenses and extending its cash runway.
ADC Therapeutics Q2 Earnings Call Highlights
ADC Therapeutics (ADCT) reported Q2 2026 net product revenue of $18.6 million for ZYNLONTA, with executives noting consistent commercial performance. The company is re-evaluating the regulatory path for its LOTIS-5 study after the FDA raised "substantial concerns" regarding its benefit-risk profile. Despite this, ADCT remains confident in ZYNLONTA's role as a single-agent treatment for third-line-plus DLBCL and does not expect the LOTIS-5 feedback to impact its existing monotherapy indication.
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS
ADC Therapeutics (NYSE:ADCT) announced its latest earnings, reporting a loss of $0.11 EPS, which beat the consensus estimate by $0.11. The company's revenue reached $19.25 million, also surpassing expectations. Key takeaways from the earnings call include FDA concerns about the LOTIS-5 combination therapy, progress in LOTIS-7 enrollment, and cost-saving measures expected to extend the cash runway.
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968
This page provides a detailed company profile for ADC Therapeutics SA, a Switzerland-based clinical-stage oncology drug discovery and development company. It outlines the company's business description, sales by activity and geographical breakdown, executive committee, board of directors, and major shareholders. Financial data, analyst consensus, and stock performance information are also included.
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall
ADC Therapeutics (ADCT) exceeded Q2 2026 earnings and revenue estimates, but its shares fell due to regulatory concerns regarding its ZYNLONTA combination program, LOTIS-5. Despite the stock drop, the company's ZYNLONTA monotherapy sales remained stable, and management expects its cash reserves to last until at least 2028. The company is evaluating its regulatory strategy for LOTIS-5 and plans to pursue breakthrough designation for its LOTIS-7 combination program.
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings
ADC Therapeutics SA (ADCT) reported its Q2 2026 earnings, posting a loss of -$0.11 per share, which beat analyst estimates of -$0.22. However, the company's revenue of $19,250,000 missed estimates by over $500,000. Insider trading activity shows significant sales by GROUP, LLC REDMILE, while hedge funds have shown mixed activity, with some increasing and others decreasing their positions.
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings
ADC Therapeutics SA (ADCT) released its Q2 2026 earnings, reporting -$0.11 per share, which beat analyst estimates. The company's revenue of $19.25 million missed estimates. The article also details recent insider trading activity, with significant sales by REDMILE GROUP, LLC, and outlines institutional investor movements, including major additions by MILLENNIUM MANAGEMENT LLC and EVENTIDE ASSET MANAGEMENT, LLC.
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss
ADC Therapeutics (ADCT) reported a narrowed GAAP loss per share in Q2 2026, reaching $0.11, primarily due to a significant 29% reduction in operating expenses, despite only a modest 2% increase in total revenue to $19.2 million. However, the company faces material regulatory uncertainty after the FDA raised concerns about the benefit-risk profile of its LOTIS-5 trial. Future growth depends on resolving these regulatory hurdles, advancing other pipeline trials, and successfully executing a workforce reorganization to manage debt and deferred royalty obligations.
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics announced its Q2 2026 financial results, with net product revenue of $18.6 million and cash reserves of $219.1 million. The company is evaluating the regulatory path for ZYNLONTA® following FDA feedback on the LOTIS-5 trial and is considering a Phase 3 trial for ZYNLONTA plus glofitamab based on promising LOTIS-7 data. The company also implemented a workforce reduction, expecting $10 million in annualized cost savings, and continues to advance investigator-initiated trials for ZYNLONTA in other B-cell malignancies.
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA is projected to report a loss of 21 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation ahead of the company's full earnings release.
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics SA (NYSE: ADCT) announced it will host a conference call and live webcast on August 13, 2026, at 8:30 a.m. EDT to report its second quarter 2026 financial results and provide operational updates. Interested parties can register for the call or access the webcast through the Investors section of the company's website. The company is a commercial-stage leader in antibody drug conjugates, with its product ZYNLONTA® approved for relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report its second-quarter 2026 financial results and provide operational updates. Interested parties can register to access the conference call or view a live webcast on the Investors section of the company's website. ADC Therapeutics is a commercial-stage global leader in antibody-drug conjugates, known for its product ZYNLONTA.
ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday
ADC Therapeutics (ADCT) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts are anticipating a loss of $0.19 per share on revenues of $18.89 million. The company's stock is currently trading around $1.08, significantly below its 52-week high, with a consensus "Hold" rating from analysts and an average price target of $6.25.
ADCT|ADC Therapeutics SA|Price:1.055|Chg%:+0.005
This article provides a comprehensive stock analysis of ADC Therapeutics SA (ADCT), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation. Despite a weak stock market performance recently, the company shows strong fundamentals and institutional confidence. Analysts have rated it as a Buy with a target price of 1.83, indicating a 74.60% upside.
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for ADC Therapeutics SA (ADCT), detailing its current risk score, industry ranking, and beta value. It presents various financial metrics including VaR, maximum drawdown, volatility, daily returns, and Sharpe Ratio over different periods. The assessment also covers liquidity measures like turnover rate and turnover deviation.
ADC Therapeutics SA (ADCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of ADC Therapeutics SA (ADCT), detailing its current price momentum score, support and resistance levels. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy, sell, or neutral signals. The analysis also features FAQs explaining technical ratings and moving averages, summarizing ADC Therapeutics SA's current technical status.
BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT)
BlackRock, Inc. has disclosed a 5.4% ownership stake in ADC Therapeutics SA, holding 6,857,815 shares of common stock. The filing indicates BlackRock has sole voting power over 6,765,332 shares and sole dispositive power over all 6,857,815 shares, with no shared powers reported. The Schedule 13G filing, signed by Managing Director Spencer Fleming, specifies that no single underlying client or investor holds more than five percent of ADC Therapeutics’ outstanding common shares.
Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT
Orbimed Advisors LLC significantly reduced its stake in ADC Therapeutics SA (NYSE:ADCT) by 77.4% in Q1, selling 4.5 million shares but retaining 1.32 million shares valued at $4.94 million. Institutional investors collectively own 41.1% of the company, which reported a quarterly loss of $0.21 per share and has a "Hold" consensus rating with a $6.25 target price. The stock opened at $1.18, trading below its 50-day and 200-day moving averages.
ADC Therapeutics SA - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It focuses on developing antibody drug conjugates (ADCs) for the treatment of various cancers, with key drug candidates ADCT-301 and ADCT-402 in clinical trials. The company's main revenue source is its Product business, and as of Q1 2026, 205 institutions hold shares in the company, accounting for 69.09% of total shares.
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of the shareholder structure for ADC Therapeutics SA (ADCT), including major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and offers a historical view of institutional shareholding changes over several quarters. The data indicates significant institutional presence and shifts in holdings by various investment firms.
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045
ADC Therapeutics SA (ADCT) is a Switzerland-based clinical-stage oncology company specializing in antibody drug conjugates (ADCs) for cancer treatment. Despite healthy fundamentals and high growth potential, its stock price has been trending down in the medium term, though analysts rate it as a "Buy" with a target price of 1.83. The company boasts significant institutional ownership and has averaged 16.96% year-on-year revenue growth over the past three years.
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Hold" rating from six research firms, with an average 1-year price target of $6.25. The company's stock recently traded at $1.23, down 1.1%, with a market cap of $155.9 million. Despite missing EPS expectations in its latest quarter, the company's revenue slightly beat estimates, and analysts anticipate -$0.88 EPS for the current year.
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation
ADC Therapeutics (ADCT) stock is stabilizing, supported by strong Zynlonta revenue growth (up 30% to $96 million in fiscal 2024), which primarily drives the company's commercial performance. Despite continued operating losses ($180 million in 2024) and high R&D spending ($130 million), the Swiss biotech maintains a substantial cash position of $270 million, allowing for a manageable cash runway. The company's valuation of CHF 240 million reflects investor caution due to development risks and ongoing losses, yet Zynlonta's market traction and pipeline potential offer future growth opportunities.
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops
ADC Therapeutics (ADCT) is experiencing steady stock performance as its revenue grows and a liquidity plan develops. The company reported a 45.7% increase in total revenue for Q1 2024, reaching $19.4 million, driven primarily by sales of its drug Zynlonta. While still operating at a loss, the company has narrowed this loss through expense reductions and is exploring strategic options to extend its cash runway.
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3% - Time to Sell?
ADC Therapeutics (NYSE:ADCT) shares dropped 6.3% on Monday, trading low at $1.26 with significantly reduced volume. Analyst sentiment is mixed, with some maintaining "overweight" while others downgraded the stock, leading to a consensus "Hold" rating and an average price target of $6.25. The company continues to face financial difficulties, reporting a wider-than-expected quarterly loss and forecasted full-year losses, with its stock trading well below its moving averages.
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
This press release details ADC Therapeutics' financial results for the first quarter of 2026 and provides operational updates. It likely includes key financial figures such as revenue, net income/loss, and expenses, along with information on clinical trial progress, regulatory submissions, or strategic partnerships. The report offers insights into the company's performance and future outlook.
ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award
ADC Therapeutics (ADCT) has granted its CFO, Jose Carmona, 203,700 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs will vest on June 30, 2027, or earlier under specific termination events, provided continued employment. This award increases his direct holdings to 938,076 common shares and is considered an equity award rather than a market transaction.
ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing
ADC Therapeutics SA's CEO, Ameet Mallik, was granted 675,000 restricted stock units (RSUs) on June 30, 2026, as reported in a Form 4 SEC filing. These RSUs, which have a price of $0.00 per unit, will vest on the earlier of June 30, 2027, or upon certain qualifying terminations of employment, contingent on continued service. Following this award, Mallik directly holds 2,121,769 common shares in the company.
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares
ADC Therapeutics' Chief Medical Officer, Zaki Mohamed, was granted 213,900 Restricted Stock Units (RSUs) on June 30, 2026, as an equity award. This compensation-related grant increases his direct holdings to 896,317 common shares. The RSUs will vest on the earlier of June 30, 2027, or a qualifying termination, contingent on his continued employment.
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer
ADC Therapeutics (ADCT) announced that its Chief Legal Officer, Peter J. Graham, was granted 221,100 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs, which represent common shares, will vest on the earlier of June 30, 2027, or specific termination events, provided he remains employed. Following this grant, Graham's direct holdings in the company now total 841,640 common shares.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (NYSE: ADCT) has announced an inducement grant of options to purchase 17,000 common shares for a new employee. This grant, approved by the Compensation Committee, aims to retain top talent and relies on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The options will vest over four years, subject to continued employment, demonstrating the company's commitment to strategic talent acquisition.
ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL
ADC Therapeutics has completed enrollment of 100 patients in its Phase 1b LOTIS-7 trial, evaluating a combination of ZYNLONTA and glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial has shown an 89.8% overall response rate and a 77.6% complete response rate in interim data. Full data from the study is expected in Q4 2026, and the company plans to explore regulatory pathways for the combination.
ADC Therapeutics completes LOTIS-7 trial enrollment
ADC Therapeutics has completed enrollment for its Phase 1b LOTIS-7 clinical trial, which investigates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 100 patients and aims to assess the safety and early efficacy of the combination therapy. Full clinical data from the trial are anticipated in the fourth quarter of 2026.
ADC Therapeutics completes enrollment in LOTIS-7 trial
ADC Therapeutics has completed enrollment in its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The company reported promising initial response rates from earlier data and anticipates sustained profitability by fiscal year 2026. Despite a recent stock decline, analysis suggests the company is undervalued, with full trial data expected by the end of 2026.
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab, with full data expected in the fourth quarter of 2026. Prior data showed promising results with an 89.8% overall response rate and 77.6% complete response.
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics has completed enrollment for its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA® in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial successfully enrolled 100 patients. Full data from the study, which has shown promising clinical activity and a manageable safety profile in earlier reports, is expected to be released in the fourth quarter of 2026.
ETFs Investing in ADC Therapeutics Ltd Stocks
This article lists several ETFs that hold ADC Therapeutics Ltd (ADCT) stocks, providing financial details for each fund. The ETFs include those focused on small-cap growth, biotechnology, micro-cap companies, and healthcare innovation, with varying management styles and expense ratios. Investors can use this information to identify funds with exposure to ADCT and assess their performance metrics.
ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index
ADC Therapeutics SA (ADCT) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement on the same day that the company was added to the Russell 2000 Value Benchmark. The company, a clinical-stage oncology drug developer, recently reported its Q1 2026 earnings and is undergoing a workforce reduction.
ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma
ADC Therapeutics (NYSE: ADCT) has completed enrollment for its LOTIS-7 Phase 1b trial, which evaluates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients across 30 sites, building on previous promising results that showed an 89.8% overall response rate and 77.6% complete response in a subset of patients. Full data from the trial are anticipated in the fourth quarter of 2026, with plans for publication and assessment of potential regulatory pathways.
Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT
This article provides financial information for ADC Therapeutics SA (NYSE: ADCT), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of TradingView's platform, indicating that the metrics are available for investor analysis. The content is primarily a data placeholder within a financial information service.
Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT
This article provides a brief financial data point for ADC Therapeutics SA (NYSE:ADCT), specifically regarding its price-to-earnings forward ratio. The content is sparse, indicating "Period Value Change Change %" but without specific numerical data. It appears to be a stub or a section focused on displaying this particular financial metric for the company.
ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT)
This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price targets, upcoming earnings dates, and past financial results like revenue and net income. The article also touches on company specifics such as employee count, EBITDA, and technical analysis recommendations.
ADC Therapeutics launches restructuring around ZYNLONTA
ADC Therapeutics (NYSE:ADCT) is undergoing a strategic reorganization focusing on its ZYNLONTA franchise and related clinical trials. The restructuring involves an estimated 17% workforce reduction, expected to save $10 million annually, and aims to extend the company's cash runway into 2028. This move highlights the company's efforts to prioritize its late-stage oncology pipeline and control costs.
ADC Therapeutics trims 17% of staff to fund ZYNLONTA push
ADC Therapeutics announced a strategic reorganization to focus resources on its ZYNLONTA franchise, which includes a 17% global workforce reduction. This move is expected to generate approximately $10 million in annualized cost savings, with one-time charges of about $3 million, extending the company’s cash runway into at least 2028. The reorganization aims to support regulatory milestones for ZYNLONTA, including an sBLA submission for LOTIS-5 in Q4 2026 and anticipated data from the LOTIS-7 trial by the end of 2026.
ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges
ADC Therapeutics announced a global workforce reduction of approximately 17% to achieve about $10 million in annualized cost savings. This reduction is primarily due to the completion of the LOTIS-5 and LOTIS-7 programs and aims to enhance financial flexibility. The company expects one-time pre-tax charges of approximately $3 million, mostly in Q2 2026, and is preparing for a pre-sBLA meeting with the FDA in August 2026 for LOTIS-5.
ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway
ADC Therapeutics announced a strategic reorganization involving a 17% global workforce reduction to focus on its ZYNLONTA franchise. This move is expected to generate $10 million in annualized cost savings against $3 million in one-time charges, extending the company’s cash runway into at least 2028. The reorganization supports key regulatory milestones, including an upcoming FDA meeting for LOTIS-5 in August 2026 and an sBLA submission in Q4 2026.
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics (NYSE: ADCT) has announced a strategic reorganization, including a 17% global workforce reduction, to enhance financial flexibility and focus on ZYNLONTA® growth. The company expects to save approximately $10 million annually, driven by the anticipated completion of LOTIS-5 and LOTIS-7 trials in 2026. Key upcoming milestones include a pre-sBLA meeting with the FDA in August 2026 for ZYNLONTA in r/r DLBCL, with an sBLA submission expected in Q4 2026, and full data from the LOTIS-7 trial by year-end.
